Trial Profile
A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects With a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms COSMEX
- Sponsors GlaxoSmithKline; GSK
- 22 Aug 2019 Results published in the Clinical Therapeutics
- 19 Sep 2018 Results assessing the the long-term safety & durability of mepolizumab in severe eosinophilic asthma patients, presented at the 28th Annual Congress of the European Respiratory Society
- 20 Nov 2017 Status changed from active, no longer recruiting to completed.